RxDoctor Payments Data

Sarah Taylor

Family · Blue Ridge, GANPI 1538868492

Payments from drug & device makers

$414in general payments, 2019–2025

Across 14 payments — averaging $29.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$172
  • GSK$63
  • Edwards Lifesciences$43
  • AbbVie$41
  • Servier Pharmaceuticals LLC$24
  • Abbott$20
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$414100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$414 in reported general payments places this provider in the 50th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$63,829
Medicare patients
169
Services billed
853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$28,247
MounjaroTirzepatide16$18,374
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$17,899
Soliqua 100-33Insulin Glargine/Lixisenatide13$10,878
Potassium Chloride31$1,195
Azelastine Hcl18$602
Atorvastatin Calcium94$595
Albuterol Sulfate HfaAlbuterol Sulfate17$579
Gabapentin39$497
Rosuvastatin Calcium44$477
Levothyroxine Sodium80$404
Losartan Potassium56$363
Famotidine26$344
Sertraline Hcl51$310
Lisinopril62$302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$18$18,37416 claims
GSKTrelegy Ellipta$63$17,89924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 6,258 family providers in Georgia.

Other family in Blue Ridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →